PK/PD
Research on the mechanism of drug–drug interaction between salvianolate injection and aspirin based on the metabolic enzyme and PK PD model: study protocol for a PK PD trial
... A combination of salvianolate and aspirin may provide an effective and safe therapeutic option for patients with CHD; however, its DDI mechanism remains unclear. We investigate this inquiry by applying a ...
8
Revealing the Neuroendocrine Response After Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling
... Abstract. To reveal unknown and potentially important mechanisms of drug action, multi- biomarker discovery approaches are increasingly used. Time-course relationships between drug action and multi-biomarker profiles, ...
12
The role of population PK-PD modelling in paediatric clinical research
... a PK or PK–PD modelling exercise is usually not just to describe the dataset of the sample of individuals that were ...of PK models are only performed in 17% of the published paediatric ...
12
Standard PK/PD concepts can be applied to determine a dosage regimen for a macrolide: the case of tulathromycin in the calf
... These values are the average serum concentrations (ng/mL) of tulathromycin over 10 incremental time intervals (0-24h, 0-48hW.0-240h) that are at least achieved by a given percentage of the calf population (Target ...
40
PK/PD analysis of biapenem in patients undergoing continuous hemodiafiltration
... on PK/PD breakpoints ...examine PK/PD breakpoint using the mean and variance of the PK ...the PK/PD breakpoint obtained for all regimens with 1 h infusion was higher than ...
10
PK-PD modelling of the interaction of propofol and midazolam : implementation and future perspectives
... The impact of the PK-PD interaction between propofol and midazolam becomes clear in the clinical scenario displayed in figure 9. In the LUMC premedication in the majority of ASA 1-2 patients is with oral ...
155
Bundling arrows: improving translational CNS drug development by integrated PK/PD-metabolomics
... A second aspect that needs to be included to provide proof of principle is the application of longitudinal metabolomics in multiple species, including humans. Taking into account the known species differences, the ...
13
Don't be afraid! Population PK-PD modeling as the basis for individualized dosing in children and critically ill
... of PK-PD models is not only to develop dosing guide- lines for the studied population, but also to predict the time course of the concentration and the effect in populations in which no information is yet ...
155
Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?
... One study has demonstrated the relationship between renal clearance and low antibiotic concentrations [14], but the relationship between renal clearance and b-lactam pharmacokinetic/pharmacodynamic characteristics has ...
9
Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon<sup>®</sup> and Eprex<sup>®</sup> following a single subcutaneous administration in healthy male volunteers
... as PD markers. Among the PD markers, the RET count was considered as the primary PD marker for the erythropoietic ...As PD parameters, maximum effect change ( Δ E max ) and the area under the ...
9
Population pharmacokinetics of methylphenidate hydrochloride extended-release multiple-layer beads in pediatric subjects with attention deficit hyperactivity disorder
... systemic PK of MPH, this is the first report of a population PK and PK/ PD model for this novel MPH-MLR product in late-stage ...MPH-population PK model using data from healthy adult ...
9
Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects
... for PK analysis. The PK-PD data obtained were analyzed using a nonlinear mixed-effects method (NONMEM ...the PK-PD model developed suggests that a 400 mg dose of moxifloxacin is also ...
13
Pharmacokinetic Pharmacodynamic modeling of the analgesic effect of bupredermTM, in mice
... established PK-PD model successfully described the relationship between plasma concentration and its analgesic efficacy measured by the tail flick ...simulate PK-PD profiles with clinical ...
8
Pharmacokinetics of Chinese medicines: strategies and perspectives
... Cellular PK–PD to address PK–PD disconnection of CMs Poor plasma concentration-efficacy/toxicity relevance is a common issue for ...the PK–PD disconnection of CMs, a cellu- lar ...
12
Integrated pharmacokinetic–pharmacodynamic modeling to evaluate empiric carbapenem therapy in bloodstream infections
... used PK/PD (%T > MIC of 40% of the dosing interval of the serum unbound drug concentration) as a surrogate for the efficacy of antimicrobial treatment to perform the cost-effective ...
6
Intracellular PD Modelling (PDi) for the Prediction of Clinical Activity of Increased Rifampicin Dosing
... the PK–PD relationship for RIF’s increasing doses, and how conventional PK–PD analyses might fall short of explaining rather complex dynamics that change over time, as well as the possibility ...
13
Effects of drug pharmacokinetic/pharmacodynamic properties, characteristics of medication use, and relevant pharmacological interventions on fall risk in elderly patients
... Two reviewers (YC and LLZ) independently searched the literature and screened the relevant studies. The num- bers of papers identified in the three databases were 750, 803, and 407, respectively. After excluding ...
12
Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam
... the PK-PD parameter of interest is the percentage of time in a dosage interval for which drug concentrations remain above the minimum inhibitory concentration (MIC) of the infecting ...the ...
7
Malaria parasite clearance
... low density gametocytaemia, and development of meth- ods which distinguish viable from dead or dying para- sites will likely improve model fits, and thus their utility in predicting therapeutic responses. Two experimen- ...
14
AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues
... The primary objective of building a robust PK-PD rela- tionship is to directly link drug exposure (e.g. dosage, plasma concentration) to PD effect in desired target tis- sue(s). Aurora-B kinase ...
12